Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of

Go back to Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of
(NASDAQ: JAGX) Delayed: 2.15 -0.13 (5.7%)
Previous Close $2.28    52 Week High $4.60 
Open $2.23    52 Week Low $0.81 
Day High $2.32    P/E N/A 
Day Low $2.15    EPS $0.00 
Volume 188,592